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Background: Refractory anemia with excess blasts subtype 1 (RAEB-1) is a subgroup of myelodysplastic syndrome.
It represents a heterogeneous group of oncohematological bone marrow diseases, which occur particularly in
elderly patients. The aim of this proteomic study was to search for plasma protein alterations in RAEB-1 patients.
Results: A total of 24 plasma samples were depleted of fourteen high-abundant plasma proteins, analyzed with 2D
SDS-PAGE, compared, and statistically processed with Progenesis SameSpots software. Proteins were identified by
nanoLC-MS/MS. Retinol-binding protein 4 and leucine-rich alpha-2-glycoprotein were relatively quantified using
mass spectrometry. 56 significantly differing spots were found; and in 52 spots 50 different proteins were
successfully identified. Several plasma proteins that changed either in their level or modification have been
described herein. The plasma level of retinol-binding protein 4 was decreased, while leucine-rich alpha-2-
glycoprotein was modified in RAEB-1 patients. Changes in the inter-alpha-trypsin inhibitor heavy chain H4, altered
protein fragmentation, or fragments modifications were observed.
Conclusions: This study describes proteins, which change quantitatively or qualitatively in the plasma of RAEB-1
patients. It is the first report on qualitative changes in the leucine-rich alpha-2-glycoprotein in the RAEB-1 subgroup
of myelodysplastic syndrome. Described changes in the composition or modification of inter-alpha-trypsin inhibitor
heavy chain H4 fragments in RAEB-1 are in agreement with those changes observed in previous study of refractory
cytopenia with multilineage dysplasia, and thus H4 fragments could be a marker specific for myelodysplastic
syndrome.
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Myelodysplastic syndrome (MDS) is a group of disorders
affecting the blood and bone marrow, characterized by
an increase in immature stem cells in the bone marrow,
together with the presence of a higher count of abnor-
mally developed cells. As a result, there is a significant
decrease of one or more blood cell lines. Refractory
anemia with excess blasts (RAEB) belongs to the group
of MDS. According to World Health Organization
(WHO) classification of MDS, two categories of RAEB
are recognized based on the count of blasts in the bone
marrow: RAEB-1 and RAEB-2 with 5-9% and 10-19%* Correspondence: pavel.majek@uhkt.cz
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reproduction in any medium, provided the ormarrow blasts, respectively [1]. RAEB-1 is characterized
by the presence of unilineage or multilineage dysplasia,
and less than 5% blasts in the blood. Patients with
RAEB-1 have a better clinical outcome than those with
RAEB-2; nevertheless, a significant proportion of RAEB-
1 patients may develop acute leukemia. Thus, specific
markers that might characterize RAEB-l and may have a
prognostic value, are currently under investigation.
Several genetic MDS studies have been published in
recent years. For example, detailed differences in the ex-
pression of miRNAs between RAEB-1 and RAEB-2 have
been observed in our institute [2]. On the contrary, very
little is known about changes in plasma or serum pro-
teins. There is a lack of proteomic data when searching
for differences between RAEB-1 with RAEB-2, or when
comparing RAEB-1 with other MDS categories. Zhongtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Two-dimensional gel electrophoresis – 2-DE) in the sera
of patients with RAEB in transformation, and suggested
a possible role of dipeptidyl peptidase (DPP/CD26) in
advanced MDS [3]. As alterations in plasma protein
levels or in posttranslational modifications of proteins
may play an important role in the disease’s mechanisms,
the knowledge of such changes may be useful in disease
diagnosis (especially when combined with modern meth-
ods using biosensors capable of fast and quantitative de-
tection in plasma or blood [4-6]), treatment, and/or
prognosis. Moreover, proteomic data could provide new
additional information that is not possible to obtain
when using genetic techniques alone [7].
The goal of our proteomic study was therefore to ex-
plore the plasma proteome of patients with RAEB-1, and
to search for possible changes relative to healthy
controls.
Methods
Patients were diagnosed with RAEB-1 according to
WHO classification criteria [1]. A total of 7 RAEB-1 pa-
tient plasma samples and 17 healthy controls were used
in the proteomic analysis. RAEB-1 patient age ranged
from 58 to 71 years, and there were 4 males (57%).
Healthy control donor age ranged from 20 to 35, and
there were 9 males (53%). All tested individuals agreed
to participate in this study and gave informed consent.
All samples were obtained and analyzed in accordance
with the Ethical Committee regulations of the Institute
of Hematology and Blood Transfusion.
Blood (10 mL) was collected by venipuncture into
tubes coated with EDTA, centrifuged (5 min, 4000xg),
and plasma aliquots were then transferred to polypropyl-
ene Eppendorf tubes and stored at −70°C until used.
There was no sample pooling (2D electrophoresis, west-
ern blotting and MS/MS based relative label-free protein
quantification) used in this study – non-pooled individ-
ual samples of patients and donors were used only.
Thawed plasma samples were centrifuged (5 min,
12000xg), and a MARS Hu-14 4.6 x 100 mm column
(Agilent, Santa Clara, CA, USA) was used to remove
fourteen high-abundant proteins (albumin, IgG, antitrypsin,
IgA, transferrin, haptoglobin, fibrinogen, alpha2-
macroglobulin, alpha1-acid glycoprotein, IgM, apolipo-
protein AI, apolipoprotein AII, complement C3, and
transthyretin), according to manufacturer instructions.
5 K MWCO Spin Concentrators (Agilent) were used to
desalinate and concentrate the samples (3000xg, 20°C).
MilliQ water (4 mL) was added to the concentrated
samples, and the desalinating-concentrating step was
repeated three times. Finally, desalinated and concen-
trated samples were vacuum dried, rapidly frozen, and
stored at −70°C.2D electrophoresis, followed by image analysis, protein
in-gel digestion and mass spectrometry identification
were performed as described in previous publications
[7-9]. Briefly, isoelectric focusing (IPG strips pI 4–7,
7.7 cm), followed by SDS-PAGE (8 x 10 cm, 10% gel,
3.75% stacking gel, 5°C, 30 mA/gel), was used in the
first and second dimension, respectively. Protein alkyl-
ation was performed during equilibration of IPG strips
before SDS-PAGE. Gels were stained using colloidal
Coomassie blue, scanned, and processed with Progen-
esis SameSpots software (Nonlinear Dynamics, Newcas-
tle upon Tyne, UK), which computed the fold change
(the fold difference of logarithms of normalized spot
volumes between the patient and control groups; the
average values of normalized spot volume logarithms of
a single spot in all samples within a group are com-
pared) and p-values of all spots using one-way ANOVA
analysis. All patient and control samples were used for
2D electrophoresis. No technical replicates were used.
Principal Component Analysis (PCA) was performed to
assess whether grouping of patients and healthy con-
trols based on proteomic methods reflects their stratifi-
cation using classical clinical diagnosis. PCA was
performed making use of the same software, focusing
only on the spots of statistical significance (based on
2D SDS-PAGE) employed for protein identification. Dif-
fering spots were excised from the gel, and the proteins
were in-gel digested with trypsin. MS/MS mass spec-
trometry (HCT ultra ion-trap mass spectrometer with
nanoelectrospray ionization; Bruker Daltonics, Bremen,
Germany) coupled to a nanoLC system (UltiMate 3000;
Dionex, Sunnyvale, CA, USA) was used to perform MS
analysis. MASCOT (Matrix Science, London, UK) was
used for database searching (Swiss-Prot release 2010_12).
To eliminate peptide carry-over between HPLC separa-
tions, cleaning runs were performed before and after
each sample run. Two unique peptides (with higher
scores than the minimum, p< 0.05) were necessary to
successfully identify a protein.
To compare the plasma levels of both leucine-rich
alpha-2-glycoprotein (LRAG) and retinol-binding pro-
tein 4 (RBP4) in patient and control samples, relative
label-free protein quantification was used on the basis of
Selected Ion Monitoring (SIM). At first, plasma proteins
were digested using modified protocols of the aceto-
nitrile precipitation of plasma proteins and trypsin diges-
tion, as described by Kay et al. [10]. Briefly, 100 μl of
water and 225 μl of acetonitrile were added to 50 μl of
plasma, and sonicated twice for 10 min with vortexing
between sonications. After centrifugation (10 min,
12000xg) 300 μl of supernatant were transferred into a
new Eppendorf tube and dried completely. Pellets were
then resuspended in 40 μl of 0.1 M NH4HCO3, 5 μl of
0.1 M DTT were added, and the samples were incubated
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iodoacetamide were added, and the samples were incu-
bated at room temperature in the dark for 30 min. Tryp-
sin digestion was induced by adding 4 μl of trypsin
(200 μg/mL) in 50 mM acetic acid and digested at 37°C
overnight. The reaction was stopped with the addition of
6.5 μl of 1% formic acid. Samples were centrifuged
(10 min, 12000xg), filtered, and 20 μl of each sample
were loaded for LC-MS/MS analysis. SIM for LRAG was
performed by monitoring two peptides: ENQLEV-
LEVSWLHGLK with precursor ion 947.5 m/z (charge
2+) and product ion 1181.8 m/z (y10) as described by
Kay et al. [11]; and TLDLGENQLETLPPDLLR with
precursor ion 1019.1 m/z (2+) and product ion
710.4 m/z (y6). SIM for RBP4 was performed by moni-
toring FSGTWYAMAK with precursor ion 589.3 m/z
(2+) and product ion 785.3 m/z (y6), and YWG-
VASFLQK with precursor ion 599.9 m/z (2+) and two
product ions – 693.4 m/z (y6) and 849.5 m/z (y8).
Peptides, precursor, and product ions were chosen on
the basis of MS/MS analysis (previous protein identifi-
cation). The nanoLC-MS/MS system was the same as
described above, but using a 60 min 0-70% acetonitrile
non-linear gradient; with a precursor selection window
width of 2 Da. Extracted ion chromatograms of the
product ions were generated with an ion m/z width
of ± 0.5 Da; and peak areas were calculated after auto-
matic integration using DataAnalysis software (version
4.0; Bruker). Each sample was measured twice. All
sample results were validated according to MS/MS
spectra and retention times [12]. Blank runs were per-
formed before and after each sample run to eliminate
peptide carry-over.Figure 1 Positions of significantly differing spots on a 2D gel. Position
patients were compared to healthy controls. The 2D gels of a patient samp
spot positions.Western blotting was performed as described previ-
ously [7]. Briefly, proteins were transferred from a gel
(corresponding to the second dimension as used in 2D
SDS-PAGE) to a PVDF membrane (10 V constant voltage
for 1 hr); the membrane was then incubated with a
blocking buffer (3% BSA in PBS) at 4°C overnight, rinsed,
and incubated with a primary antibody anti-ITIH4
(Abnova, Taipei, Taiwan); 1:2000 dilution, at 30°C for
45 min. The membrane was then incubated with the sec-
ondary antibody (rabbit anti-mouse IgG antibody conju-
gated with peroxidase; Sigma-Aldrich, Prague, Czech
Republic), 1:60000 dilution, at 30°C for 45 min. After
rinsing, a chemiluminescent substrate (SuperSignal West
Pico; Thermo Scientific, Waltham, MA, USA) was added
to the membrane for 5 min; and an appropriate film ex-
position (Amersham Hyperfilm ECL; GE Life Sciences,
Piscataway, NJ, USA) was performed.
Results
Comparing the RAEB-1 group (n = 7) with the con-
trol group (n = 17), 56 spots that differed significantly
(p< 0.05, ANOVA) in their normalized volumes were
found (Figure 1). Proteins in 52 spots were successfully
identified using MS/MS, and corresponded to 50 unique
proteins. All spots and identified proteins are summar-
ized in the list of spots; including ANOVA p-value, fold
change, protein identification with the number of identi-
fied peptides (unique peptides above the threshold score),
protein accession number (Swiss-Prot), and sequence
coverage (See additional file 1: Table S1). An example of
four spots presented in Table S1 is shown in Figure 2.
Fragmentation of the inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4) was observed in several spotss of all spots that were found to differ significantly when RAEB-1
le (A) and a healthy control (B) were used as illustrative gels to display
Figure 2 An example of four detected spots. Expression profiles with the logarithms of spot normalized volumes and their standard
deviations for RAEB-1 patient and healthy control groups are presented for four (19, 21, 25, and 30) spots.
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ence of co-identified proteins in all spots except spot 19,
a trend of decreased normalized volumes of each spot in
RAEB-1 was observed, when compared with the control
group. Comparing the sequences of ITIH4 identified
peptides (using MS/MS) in all spots with the observed
fragmentation, these peptides corresponded to the
35 kDa ITIH4 processed protein. In addition, the mo-
lecular weights of the spots with the observed ITIH4
fragmentation, as estimated using 2D SDS-PAGE, corre-
sponded to that of 35 kDa ITIH4. Uncleaved ITIH4 was
identified in spot 41.
Principal Component Analysis showed an obvious
separation of samples into two aggregates, corresponding
to the RAEB-1 and control groups (Figure 3).
Relative label-free quantification of LRAG and RBP4
was performed using all seven RAEB-1 samples (the
same samples as used in 2D SDS-PAGE) and compared
to seven sex-matched control samples from healthy
donors. Each sample was measured twice, and average
values of peak areas of peptides in patient and controlgroups were compared. Quantification of LRAG showed
different fold change values for its peptides. The average
peak area value was more than two-fold decreased in the
MDS group (2.24-fold) when compared with the control
group for 1019.1/710.4, while there was no obvious dif-
ference for 947.5/1181.8 (1.08-fold). Quantification of
RBP4 showed a decrease in the both measured peptides
in the MDS group. There were two product ions
(693.4 m/z – y6, and 849.5 m/z – y8) measured for
YWGVASFLQK (599.9 m/z) to establish which would be
suitable to use for SIM or possible Selected Reaction
Monitoring (SRM). Both transitions were found to be
suitable and stable with similar results. For both there
was more than a three-fold decrease in the MDS group
when compared with the control group (3.21-fold and
3.29-fold for 599.9/693.4 and 599.9/849.5, respectively).
For the second RBP4 peptide (589.3/785.3), more than a
two-fold decrease (2.33-fold) was observed in the patient
group. The results are summarized in Table 1.
The plasma level of uncleaved ITIH4 was assessed by
western blot analysis. No difference in ITIH4 expression
Figure 3 Principal Component Analysis. PCA was performed to assess whether grouping of patient and healthy controls based on proteomic
methods (2D SDS-PAGE) reflects their stratification using classical clinical diagnosis. Analysis was based on spots that significantly differed
according to the mentioned statistical criteria (p< 0.05, ANOVA). PCA showed the separation of all samples into two aggregates that
corresponded to the RAEB-1 (blue dots) and healthy control group (pink dots).
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(n = 7) was observed.
Discussion
Changes in the plasma proteome of RAEB-1 patients are
presented in this paper. Further, two proteins, leucine-
rich alpha-2-glycoprotein and retinol-binding protein 4
that were uniquely identified within their spots and
could be of interest as they have not been associated
with MDS before, were quantified relatively using SIM
to validate the data obtained by 2D electrophoresis. The
criteria for selection of the two proteins for further val-
idation were their unique identification within a spot,
fold, and p-values. As the presence of other proteins in a
spot may influence the spot normalized volume and
consequently the fold and p-value, we did not consider
non-uniquely identified proteins for further validation
(relative quantification).
When summarizing our data, the main factor that
seemed to influence the results and participate the most
in plasma proteome changes was inflammation. The ma-
jority of the identified proteins that changed were proteins
of acute phase reaction and those involved in inflamma-
tion response: C-reactive protein, prothrombin, comple-
ment proteins, alpha-1-antichymotrypsin, albumin, etc.Table 1 Relative label-free quantification of proteins






LRAG (leucine-rich alpha-2-glycoprotein), RBP4 (retinol-binding protein 4).These results are in agreement with the previously shown
involvement of inflammation in MDS [13-15]. Inflamma-
tion and expression of the inflammation response proteins
are closely related to apoptosis and to the production of
inflammatory cytokines, a unifying factor of different
MDS subgroups.
In this study, alterations of the inter-alpha-trypsin in-
hibitor heavy chain H4 (ITIH4) fragments were
observed. ITIH4 is a protein involved in acute phase re-
action and is considered to be a possible marker of can-
cer [16]. Its fragments have been found to be potentially
associated with MDS [17]; with differences in the frag-
mentation of ITIH4 having been shown in literature
[16,18] and related to several malignant diseases [18-21].
Moreover, changes in the composition or modifications
in ITIH4 fragments were observed in our previous
proteomic study describing plasma proteome changes in
another MDS subgroup – refractory cytopenia with mul-
tilineage dysplasia (RCMD) [22]. In RAEB-1, ITIH4 pep-
tide sequences (according to MS/MS) and spot
molecular weights (estimated by 2-DE) corresponded to
the 35 kDa processed ITIH4 protein (as processed by
kallikrein) in all spots except spot 41, which corre-
sponded to uncleaved ITIH4. Normalized volumes of
the spots containing processed 35 kDa ITIH4 fragmentsor charge Product ion [m/z] Product ion fold (N/MDS)
2+ 710.4 y6 2.24
2+ 1181.8 y10 1.08
2+ 785.3 y6 2.33
2+ 693.4 y6 3.21
2+ 849.5 y8 3.29
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patients [22]. Uncleaved ITIH4 plasma levels estimated
with western blotting in both RAEB-1 and RCMD
patients, and also in control groups were the same.
Therefore, the increase of normalized volumes of spots
containing uncleaved ITIH4 (both in RAEB-1 and
RCMD) was most likely caused by co-identification. As
the results for ITIH4 fragments in the RAEB-1 group
are the same as in RCMD patients (spot positions within
2D maps, fold changes, estimated fragment molecular
weights, and western blot analysis results) we suppose
that the changes in the composition or modifications of
ITIH4 fragments may be specific for all myelodysplastic
syndromes and not only for its subgroups. Nevertheless,
comparisons of the plasma proteomes of other MDS
subgroups are necessary to draw further conclusions.
The results obtained by 2-DE concerning ITIH4 frag-
ments may be explained by a progressive fragmentation
of ITIH4 fragments in the patient group producing
smaller fragments (which could not be detected by 2-DE
as used in our study); as well as also the possibility of
posttranslational modifications. Nevertheless, in light of
the observations from RAEB-1, RCMD, and previous lit-
erature [17] it seems that ITIH4 alterations could be a
marker specific for myelodysplastic syndrome.
Leucine-rich alpha-2-glycoprotein (LRAG) was identi-
fied in two spots (31 and 36), with normalized volumes
increased in RAEB-1 by 1.7- and 1.5-fold, respectively.
LRAG, isolated for the first time in 1977 by Haupt and
Baudner [23], contains 8 repeating sequences (each con-
sisting of 24 amino acids) termed leucine-rich repeat
(LRR). Since the first isolation and identification of this
protein, many proteins have been identified to contain
LRR sequences, probably playing a significant role in
protein-protein interactions. The physiological function
of LRAG remains unknown, although some clues have
been observed (LRAG was proposed to possibly be
involved in the innate immune response) [24]. It has
been also suggested that LRAG may be a marker of
granulocytic differentiation; moreover, it was reported
that its expression was up-regulated during neutrophil
differentiation [25]. Altered serum expression (up-regulation)
of LRAG was observed in several diseases, for example
in lung cancer [26] and pancreas cancer [27]. It has
been reported that the expression of LRAG in hu-
man hepatoma cells was induced by IL-6, IL-1β, and
TNFα; and that the LRAG expression was enhanced by
the induction of acute inflammation in mice [24]. As the
LRAG alteration in RAEB-1 using 2D electrophoresis
was observed, a relative quantification using mass spec-
trometry was further performed to establish whether the
LRAG change was based on the altered expression only,
or if it was affected by posttranslational modification.
The need for confirmation was supported by the factthat LRAG was identified in two spots with the same
molecular weight but different pI, indicating the pres-
ence of posttranslational modification(s) (for example,
LRAG glycosylation has been observed [28-30]; however,
this was not examined in this study). The relative quan-
tification of two LRAG peptides showed completely dif-
ferent results when compared to 2D electrophoresis
results: the first peptide (SIM of 947.5/1181.8) was not
altered at all, while the second peptide was actually
decreased more than twice in the MDS group. This dif-
ference proved the presence of posttranslational modifi-
cation(s) of LRAG in MDS (no alterations in different
peptides of the same protein should be present in case
of level change only), and it is likely that the LRAG
plasma level is not changed. However, the possibility of
LRAG plasma level changes has not been excluded. In
our previous study of RCMD, LRAG was identified only
in one spot and as the only protein in the spot [22]. Even
though the number of plasma samples was substantially
higher than in this RAEB-1 study (22 RCMD patients
and 24 controls), the p-value was higher (p = 0.043) and
the fold value was lower (1.3). Therefore, LRAG or its
modification(s) could be a RAEB-1 specific marker.
Retinol-binding protein 4 (RBP4) was identified in spot
30, with its normalized volume decreased in RAEB-1 by
1.7-fold. RBP4 is a specific carrier protein for retinol,
which is delivered from the liver to the peripheral tis-
sues. The binding of retinol to RBP4 facilitates the trans-
fer of retinol, which is insoluble in aqueous solutions
[31]. It has been shown that RBP4 is associated with
variables related to insulin resistance and diabetic com-
plications [32]; an increased level of plasma RBP4
increases insulin resistance by inhibiting insulin signal-
ing [33]. RBP4 was also considered to be involved in in-
flammation, but no correlation was found between RBP4
and C-reactive protein in a study of RBP4 in type 2 dia-
betes patients [32]. In a more recent study, the RBP4
serum level was significantly reduced in critically ill
patients independently of sepsis (as compared with the
healthy control group), and their RBP4 level was closely
correlated with liver function [34]. Finally, acute phase
proteins were inversely correlated with RBP4 in sepsis
patients. As in the case of leucine-rich alpha-
2-glycoprotein, relative quantification using mass spec-
trometry (SIM) was performed to differentiate between
the RBP4 plasma level change and possible posttransla-
tional modification. Two RBP4 peptides were monitored
and two product ions (y6 and y8) of the first peptide
were measured (599.9/693.4 and 599.9/849.5) to find a
proper transition. Both y6 and y8 product ions were
found to be suitable with a stable response and duplicate
results: a decrease in the MDS group of 3.21-fold and
3.29-fold, which averages 3.25-fold for the first peptide.
The second RBP4 peptide was decreased as well with a
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with those observed by 2D electrophoresis, suggesting
that the RBP4 plasma level is markedly decreased in
RAEB-1 patients. In our previous study of RCMD, RBP4
was co-identified in one spot only; moreover, its normal-
ized volume was increased in RCMD in contrast to
RAEB-1 results. Therefore, it seems that RBP4 could be
a RAEB-1 specific marker. It will nevertheless, be neces-
sary to compare our results to other MDS subgroups to
determine whether the decrease of the RBP4 plasma
level is related to MDS pathophysiology specific for
RAEB-1, or if it is a result of inflammation, as the RBP4
is a negative acute phase protein and its level is
decreased during the inflammatory response.
An additional issue that must be discussed is the dis-
parity of age ranges between the patient and healthy
control groups. The optimal control group should of
course match for age as well as for sex. As MDS usually
occurs in elderly patients, there should be a control
group of a similar age range. However, this matching
may contribute to other limitations – the primary diffi-
culty is to find healthy individuals of older age, who do
not suffer from other complicating diseases. These vari-
ables may significantly affect our obtained results. More-
over, MDS is not exclusively limited to elderly patients
only. The problem of collecting and matching of the
control groups including our methodology and further
justification was discussed in detail in our previous MDS
study [22].
Conclusions
In conclusion, this study represents the first report on
the qualitative alteration in leucine-rich alpha-2-
glycoprotein, and the change in retinol-binding protein
4 in the plasma of MDS patients with RAEB-1. The
changes in both proteins seem to be specific for RAEB-1
, when compared to another subgroup of myelodysplas-
tic syndrome – refractory cytopenia with multilineage
dysplasia. We may speculate that this alteration of
LRAG may reflect the impairment of granulocyte differ-
entiation, which is linked to disease progression. Since
the level of proapoptotic cytokines affects the level of
both proteins, we may also speculate that their decrease
might reflect a decreased rate of apoptosis, also con-
nected with a progressive disease. Furthermore, changes
in the composition or modifications of the inter-
alpha-trypsin inhibitor heavy chain H4 fragments were
observed. These changes were in agreement with those
observed in the refractory cytopenia with multilineage
dysplasia subgroup of MDS. Proteomic studies of other
MDS subgroups will help to find proteins that are uni-
versally changed in MDS when compared with the
healthy population, or specifically altered in different
subgroups of MDS.Additional file
Additional file 1: Table S1. List of spots that differ significantly when
RAEB-1 patients and healthy controls were compared.
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